Involvement of the nuclear factor-kappaB (NF-êB) pathway in peritoneal endometriosis

Endometriosis is a gynecological disease in which endometrial glands and stroma are present outside the uterus. Pelvic pain, infertility and decreased quality of life are the main problems caused by this disease carrying epidemiological and social impact. Peritoneal endometriosis which is characterized by the presence of red, black and white pelvic endometriotic lesions is clearly a multifactorial pathology associated with a local inflammatory response in the pelvic cavity. In vitro studies suggest that the transcription factor nuclear factor-kappaB (NF-êB) is implicated in the transduction of proinflammatory signals in endometriosis. The aim of this study was to investigate the involvement and role of the NF-êB pathway in endometriosis in vivo. Firstly, NF-êB activation and intercellular adhesion molecule (ICAM)-1 expression were investigated in thirty-six peritoneal endometriotic lesions from women. Constitutive NF-êB activation, involving p65- and p50-containing dimers, was demonstrated in peritoneal endometriotic lesions by electrophoretic mobility shift assays and supershift analyses, as well as NF-êB (p65) DNA-binding activity immunodetection assays. NF-êB activation and ICAM-1 expression were significantly higher in red lesions than black lesions, while IêBá (NF-êB inhibitory protein) expression was constant, as shown by Western blot analyses. Secondly, endometriosis was induced in nude mice by intraperitoneal injection of fluorescent labeled menstrual endometrium. Two NF-êB inhibitors (BAY 11-7085 and SN-50) were injected intraperitoneally and endometriotic lesions were recovered on day 5. Both NF-êB inhibitors induced a significant reduction in lesion development compared to control mice. NF-êB activation and ICAM-1 expression of endometriotic lesions were significantly reduced in treated mice, and cell proliferation in BAY 11-7085-treated mice. Both inhibitors produced a significant increase in apoptosis of endometriotic lesions, as assessed by active casp
(MED 3)--UCL, 2007